+

WO2005025604A3 - Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique - Google Patents

Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique

Info

Publication number
WO2005025604A3
WO2005025604A3 PCT/US2004/029540 US2004029540W WO2005025604A3 WO 2005025604 A3 WO2005025604 A3 WO 2005025604A3 US 2004029540 W US2004029540 W US 2004029540W WO 2005025604 A3 WO2005025604 A3 WO 2005025604A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb
box
fragments
immune response
specific immune
Prior art date
Application number
PCT/US2004/029540
Other languages
English (en)
Other versions
WO2005025604A2 (fr
Inventor
Howland Shaw Warren Jr
Kevin J Tracey
Original Assignee
Gen Hospital Corp
Long Island Jewish Res Inst
Howland Shaw Warren Jr
Kevin J Tracey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Long Island Jewish Res Inst, Howland Shaw Warren Jr, Kevin J Tracey filed Critical Gen Hospital Corp
Publication of WO2005025604A2 publication Critical patent/WO2005025604A2/fr
Publication of WO2005025604A3 publication Critical patent/WO2005025604A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés pour traiter une pathologie immunitaire chez un individu, comprenant l'administration audit individu d'une quantité efficace d'un polypeptide protéine du domaine du groupe à mobilité élevée (high mobility group box protein / HMGB), comprenant un domaine de HMGB A de vertébré, un domaine de HMGB A d'origine artificielle, ou un fragment immunosuppresseur dudit domaine de HMGB1 A de vertébré ou du domaine de HMGB1 A d'origine artificielle.
PCT/US2004/029540 2003-09-10 2004-09-10 Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique WO2005025604A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50234903P 2003-09-10 2003-09-10
US60/502,349 2003-09-10

Publications (2)

Publication Number Publication Date
WO2005025604A2 WO2005025604A2 (fr) 2005-03-24
WO2005025604A3 true WO2005025604A3 (fr) 2005-06-09

Family

ID=34312386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029540 WO2005025604A2 (fr) 2003-09-10 2004-09-10 Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique

Country Status (1)

Country Link
WO (1) WO2005025604A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514835A (pt) * 2004-09-03 2008-06-24 Creabilis Therapeutics Spa variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico
WO2007031100A1 (fr) * 2005-09-14 2007-03-22 Ostini, Marco Immunothérapie active pour inflammation systémique potentiellement mortelle
JP4982739B2 (ja) * 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
KR20110017371A (ko) 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
EP2494977B1 (fr) 2009-10-28 2018-06-13 Genomix Co., Ltd. Promoteur de régénération tissulaire utilisant le recrutement de cellules souches mésenchymateuses de moelle osseuse ou de cellules souches pluripotentes dans le sang
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CN103097399A (zh) 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
AU2011299025B2 (en) 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
KR101992807B1 (ko) 2011-04-26 2019-06-26 가부시키가이샤 스템림 조직 재생을 유도하기 위한 펩티드 및 그의 이용
CN104955470B (zh) 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
SG11201503236RA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
CA2900644C (fr) 2013-02-14 2023-03-14 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour renforcer des reponses immunitaires vis-a-vis d'eimeria ou limiter une infection par eimeria
SG11201507421XA (en) 2013-03-15 2015-10-29 Univ Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
WO2018170178A1 (fr) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition et procédés de rupture de biofilms bactériens sans inflammation associée
WO2019107530A1 (fr) * 2017-12-01 2019-06-06 株式会社ステムリム Agent thérapeutique pour une maladie inflammatoire de l'intestin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092004A2 (fr) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Utilisation de fragments de hmg en tant qu'agents anti-inflammatoires
WO2004046338A2 (fr) * 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Utilisation de polypeptides hmgb permettant d'accroitre des reponses immunitaires
WO2004046345A2 (fr) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092004A2 (fr) * 2001-05-15 2002-11-21 North Shore-Long Island Jewish Research Institute Utilisation de fragments de hmg en tant qu'agents anti-inflammatoires
WO2004046338A2 (fr) * 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Utilisation de polypeptides hmgb permettant d'accroitre des reponses immunitaires
WO2004046345A2 (fr) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires

Also Published As

Publication number Publication date
WO2005025604A2 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2005025604A3 (fr) Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique
GEP20105059B (en) Anti-cd154 antibodies
WO2004075861A3 (fr) Production de virus recombines adeno associes
ZA200409186B (en) Specific antibodies to amyloid beta peptide, pahrmaceutical compositions and methods of use thereof.
WO2005049073A3 (fr) Proteines appartenant a la famille bcl-2, fragments associes, et utilisation therapeutique de ces proteines et fragments sur des patients atteints du cancer
WO2004043361A3 (fr) Compositions et procedes de traitement des maladies liees aux cellules k naturelles
ATE522541T1 (de) Bakterielle adhäsine konformere
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
PL1675956T3 (pl) Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek
WO2006019804A3 (fr) Compositions et methodes de purification de glycoproteine associee a la myeline (mag)
WO2005035570A3 (fr) Nouveaux variants de la proteine cd40l
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
WO2001083739A3 (fr) Polypeptides pellino humains
WO2003000719A8 (fr) Produit antigenique manifestant plusieurs copies d'un epitope d'un polypeptide formant des depots implique dans des maladies a formation de plaques et procedes d'utilisation correspondants
IL152406A0 (en) Anti-freeze proteins, their production and use
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2003093419A3 (fr) Prevention de lymphoedeme secondaire avec un adn de vegf-d
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2003106478A3 (fr) Anticorps se liant a l'integrine alphae
WO2003059281A3 (fr) Nouveaux variants de proteines rankl
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant
GB0120022D0 (en) Conjugate
WO2006002195A3 (fr) Procede de complexation d'une proteine au moyen d'un systeme disperse et proteines ainsi obtenues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载